Company is under investigation for potential securities fraud related to delayed release of critical phase 3 clinical trial results. Stock experienced significant 13.15% decline following the news of the delayed results announcement.
Articles that tag SLS but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
